GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

NCT06851247 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Toripalimab
DRUG: Anlotinib
DRUG: Gemcitabine
DRUG: Cisplatin
RADIATION: radiation

Sponsor

Sun Yat-sen University